Investigational drug · Phase 2
TU2218
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Solid Tumor, Solid Tumor, Biliary Tract Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 30, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "TU2218"
First trial start
2021
Dec 2, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TU2218", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Tumor
- Solid Tumor
- Biliary Tract Cancer
- Head and Neck Squamous Cell Carcinoma
- Colorectal Cancer
Approved drugs for the same conditions: Colorectal cancer · Head and neck cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "TU2218" as an intervention, largest first.
TiumBio Co., Ltd.Industry
NCT05204862 · 240 participants (planned) · Start Dec 2, 2021 · Primary completion Jun 30, 2026
Drug: TU2218; Anti-PD-1 antibody · For: Advanced Solid Tumor
Sites: San Antonio, Texas; Seoul, South Korea · 3 sites in all
- Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid TumorsRecruiting
TiumBio Co., Ltd.Industry
NCT05784688 · 140 participants (planned) · Start Mar 10, 2023 · Primary completion Dec 2026
Drug: TU2218 + KEYTRUDA® (Pembrolizumab) · For: Solid Tumor; Biliary Tract Cancer; Head and Neck Squamous Cell Carcinoma and 1 more
Sites: San Antonio, Texas; Tyler, Texas; Spokane, Washington · 11 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- ALK5/VEGFR2 dual inhibitor TU2218 alone or in combination with immune checkpoint inhibitors enhances immune-mediated antitumor effects.
Kim NH, Lee J, Kim SH, et al. · Cancer Immunol Immunother 2024
Also in development for Advanced Solid Tumor
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- LBL-024Phase 311 trials
Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- R-DXdDS 6000a, MK-5909Phase 310 trials
Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- QLC5508MHB088CPhase 39 trials
Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.